Oncogene alterations in primary, recurrent, and metastatic human bone tumors

Pompetti, Franca; Rizzo, Paola; Simon, Richard; Freidlin, Boris; Mew, Daphne; Pass, Harvey I.; Picci, Piero; Levine, Arthur S.; Carbone, Michele

doi:10.1002/(sici)1097-4644(199610)63:1<37::aid-jcb3>3.0.co;2-0

Cited by 88 publications

(33 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38,39 Although we observed a high-level gain of 8q23-q24 in 24% of cases, MYC (8q24.12-q24.13) amplification has been reported to occur in only 7-12% of osteosarcomas. 40,41 Tarkannen et al 21 reported that a copy-number increase at 8q represents a statistically significant poor prognostic factor; we arrived at this same conclusion for 8q gains, but only when present in combination with losses of 13q14.…”

Section: Event-free Survival (Efs) In 41 Patients With Primary Tumorsupporting

confidence: 79%

Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas

Ozaki

Schaefer

Wai³

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

Section: Event-free Survival (Efs) In 41 Patients With Primary Tumorsupporting

confidence: 79%

Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas

Ozaki

Schaefer

Wai³

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

“…Several proto-oncogenes are known to be expressed in osteosarcomas [3,17,19,26,30], but their roles in the pathogenesis of these tumors are incompletely understood. Likewise, the roles of proto-oncogenes in the development of other musculoskeletal lesions remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Detection of c‐fos expression in benign and malignant musculoskeletal lesions

Weisstein

Majeska

Klein

et al. 2001

Journal Orthopaedic Research

View full text Add to dashboard Cite

The proto-oncogene c-fos has been implicated in the development of both benign and malignant lesions of bone. Although c-fos expression in such lesions has been well studied in transgenic mouse models, less is known about its role in human musculoskeletal pathology. To clarify this relationship, we used in situ hybridization to localize c-fos m-RNA transcripts in 26 fibrous lesions (eight cases of extra-abdominal fibromatosis and six cases each of fibrous dysplasia, fibrosarcoma, and malignant fibrous histiocytoma of bone) as well as six chondrosarcomas and eight conventional high grade osteosarcomas. We found detectable levels of c-fos expression in tissues from each type of lesion tested. Moreover, all fibrous lesions consistently demonstrated high levels of expression in a majority of cells in each lesion. Chondrosarcomas and osteosarcomas exhibited more heterogeneity in c-fos expression than fibrous tissues. Three of six chondrosarcomas showed moderate expression of c-fos while only one of six was considered high. Similarly, only three of eight osteosarcomas had high expression of c-fos. These findings indicate that the expression of c-fos may be important in the development of a broad range of fibrous lesions as well as in bone and cartilaginous tumors. Additionally, this is the first report, to our knowledge, of detectable c-fos m-RNA in human chondrosarcoma.

show abstract

“…However, to our knowledge, H-ras mutations in chondrosarcoma have not been previously reported. On the contrary, it has been reported that none of six chondrosarcomas demonstrated ras gene mutations (K-ras, H-ras, and N-ras) at codons 12, 13, and 61 (15), and that neither of two chondrosarcomas showed H-ras mutation at codon 12 (16). This document would therefore seem to be the first report to verify the presence of H-ras mutation in a series of chondrosarcoma.…”

Section: Discussionmentioning

confidence: 53%

“…As for sarcomas, H-ras mutations have been reported in MFH, leiomyosarcoma, and rhabdomyosarcoma (11)(12)(13)(14); however, H-ras mutations have not been reported in chondrosarcomas. Moreover, H-ras mutations were not detected in two previous series of chondrosarcoma (15,16), and the contribution of H-ras mutation to dedifferentiation has not been fully examined.…”

mentioning

confidence: 96%

H-ras Oncogene Mutation in Dedifferentiated Chondrosarcoma: Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Analysis

et al. 2001

View full text Add to dashboard Cite

Dedifferentiated chondrosarcomas, which are known for their poor prognosis, are characterized by conventional chondrosarcoma with high-grade anaplastic components. Activating mutations in ras genes are a common genetic abnormality in human malignancies. The presence of point mutations at codons 12 and 13 of the H-ras gene was studied in 20 formalin-fixed paraffin-embedded chondrosarcomas, comprising 11 cases of conventional chondrosarcoma (six Grade 1 cases and five Grade 2 cases) and nine cases of dedifferentiated chondrosarcoma, using polymerase chain reactionrestriction fragment length polymorphism and direct sequencing analysis. H-ras mutations were only seen in two out of the nine cases of dedifferentiated chondrosarcoma (2/9, 22%) and they were not seen in any of the cases of conventional chondrosarcoma (0/11, 0%). Dedifferentiated chondrosarcomas had a worse prognosis than conventional chondrosarcomas (P < .01); among the patients with dedifferentiated chondrosarcomas, those with H-ras mutation (n ‫؍‬ 2) tended to have a worse prognosis than those without (n ‫؍‬ 7), although the difference was not statistically significant (P ‫؍‬ 0.068). Our results would seem to suggest that H-ras mutation may occur during the course of dedifferentiation and may also have some effect on malignant potential.

show abstract

Oncogene alterations in primary, recurrent, and metastatic human bone tumors

Cited by 88 publications

References 21 publications

Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas

Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas

Detection of c‐fos expression in benign and malignant musculoskeletal lesions

H-ras Oncogene Mutation in Dedifferentiated Chondrosarcoma: Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Analysis

Contact Info

Product

Resources

About